PRODUCT IDENTIFICATION

H.S. CODE

TOXICITY

(16alpha,17beta)-Estra-1,3,5(10)-triene-3,16,17-triol; (16alpha,17beta)-Oestra-1,3,5(10) -triene-3,16,17-triol; 1,3,5(10)-Estratriene-3,16alpha,17beta-triol;  16alpha-Hydroxyestradiol; 3,16alpha,17beta-Trihydroxy-1,3,5(10)-estratriene; 1,3,5-Estratriene-3beta,16alpha,17beta-triol; 1,3,5-Oestratriene-3beta,16alpha,17beta-triol; 16-alpha,17-beta-Estriol; 16-alpha,17-beta-Oestriol; 16-alpha-Hydroxyestradiol; Destriol; 16-alpha-Hydroxyoestradiol; 16alpha,17beta-Estriol; 16alpha,17beta-Oestriol; 16alpha-Hydroxy-17beta-estradiol; 16alpha-Hydroxyestradiol; 16alpha-Hydroxyoestradiol; 3,16-alpha,17-beta-Estriol; 3,16-alpha,17-beta-Oestriol; 3,16-alpha,17-beta- Trihydroxy-delta-1,3,5- estratriene; 3,16-alpha,17-beta-Trihydroxy-delta-1,3,5 -oestratriene; 3,16-alpha,17-beta-Trihydroxyestra- 1,3,5(10)-triene; 3,16-alpha,17-beta-Trihydroxyoestra -1,3,5(10)-triene; 3,16alpha,17beta-Estriol; 3,16alpha,17beta-Trihydroxy-1,3,5(10)-estratriene; 3,16alpha,17beta-Trihydroxy-delta-1,3,5 -oestratriene; Estra-1,3,5(10)-trien-3,16alpha,17beta-triol; Estra-1,3,5(10)-triene-3,16alpha, 17beta-triol; Estratriol; Estriolo; Follicular hormone hydrate; Oestra-1,3,5(10)-triene-3,16-alpha,17 -beta-triol; Oestra-1,3,5(10)- triene-3,16alpha,17beta-triol; Oestratriol; Oestriol; Oestriolum; Orestin; Orgastyptin; Thulol; Tridestrin; Trihydroxyestrin; Trihydroxyoestrin; Triodurin; Triovex; Delta(1,3,5-10)-estratriene-3,16-cis-17-trans-diol; íÁß²âõ;

[C@H]12[C@H]3[C@@H](c4c(CC3)cc(cc4)O)CC[C@@]1 ([C@H]([C@@H](C2)O)O)C

CLASSIFICATION

Steroid, Estrogen, Hormone, Biochemicals ex Plants

PHYSICAL AND CHEMICAL PROPERTIES

white to almost white crystalline powder

SOLVENT SOLUBILITY

REFRACTIVE INDEX

GENERAL DESCRIPTION & EXTERNAL LINKS

Wikipedia Linking: http://en.wikipedia.org/wiki/Estriol

http://www.reciprocalnet.org/
Estriol is a human female sex hormone. It is produced by the placenta. Only during pregnancy it present in the body at significant levels. Pharmaceutical companies suggest its use in ¡°anti-aging¡± therapy and to alleviate menopausal effects. However, any hormone therapy interferes with natural processes in the body. Hormone therapies have been linked to certain cancers (e.g. breast cancer) and other health problems

http://clinicaltrials.gov/show/NCT00908570
There is evidence from human studies that estrogen can give rise to health-promoting changes in the vaginal environment in addition to affecting the thickness of the vaginal epithelium. The purpose of the proposed study is to take the first steps in testing the effects of local estrogen treatment on vaginal health parameters in humans. We have chosen an estriol product because, in comparison with estrone (E1) and estradiol (E2), estriol (E3) is generally considered to be a weak estrogen. The duration of estriol's interaction with the estrogen receptor is quick and exhibits rapid metabolic clearance. We have chosen a topical route of administration because it appears to result in fewer systemic effects than oral administration, while allowing us to concentrate treatment locally in the areas we wish to affect.
Our primary goal is to test whether or not topically applied estrogen results in significant thickening and maturation of the vaginal epithelium. Our secondary goal is to measure the treatment's effects on other parameters of the vagina, such as Lactobacillus colonization and vaginal pH. If estrogen cream does indeed affect the vaginal environment in pre-menopausal women as it does in post-menopausal women, further study would be indicated to determine whether estrogen cream in the vagina decreases risk of infection in pre-menopausal women.

APPEARANCE

white to almost white crystalline powder

ASSAY

RESIDUES ON IGNITION

0.1% max

LOSS ON DRYING

0.5% max

HEAVY METALS

10ppm max

SPECIFIC ROTATION

+54° ~ +62°

PARTICLE SIZE

20 ¥ìm

Hazard Symbols:T, Risk Phrases:60-61-40, Safety Phrases:53-22-36/37/39-45